Medication info
Trinam 2.5/850 mg (Linagliptin, Metformin)

Trinam 2.5/850 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Orange, double convex oval film-coated tablets
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401053 · Approved 2024.04.30

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be determined for each patient based on their current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each ingredient: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with diabetes drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution in Use). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution in Use). Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

View approved original text

This medication is used as part of a treatment regimen alongside dietary changes and exercise to assist patients with type 2 diabetes in controlling their blood sugar levels. It combines the active ingredients linagliptin and metformin to effectively help regulate blood glucose levels, thus improving blood sugar levels for diabetes management.

How to take

Adult dose

The dose of this medicine should be determined for each patient based on their current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended dose of each ingredient: linagliptin 2.5 mg (linagliptin besylate 3.34mg) and metformin 1000 mg twice daily. This medicine should be administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior experience with diabetes drug therapy whose blood glucose cannot be adequately controlled with monotherapy, the initial dose of this medicine is 1 tablet of 2.5/500 mg twice daily; the dose may be increased to 1 tablet of 2.5/1000 mg twice daily. 2. Patients whose blood glucose cannot be adequately controlled with metformin monotherapy: The initial dose of this medicine should be linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current metformin dose (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Patients switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose cannot be adequately controlled with combination therapy with metformin and a sulfonylurea: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution in Use). 5. Patients whose blood glucose cannot be adequately controlled with combination therapy with insulin and metformin: The initial dose of this medicine should be considered as linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is coadministered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution in Use). Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who have no other condition that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Is Contraindicated).

Precautions

This medication can cause a rare but serious side effect called lactic acidosis, so it should not be administered to individuals with poor kidney function or acute illness. It should not be used in patients with an allergy to any of its components, those with type 1 diabetes, pregnant or breastfeeding women, or patients with severe liver dysfunction. There is a risk of hypoglycemia, particularly when used alongside sulfonylureas or insulin; blood glucose levels should be monitored closely. Patients with reduced kidney function should regularly have blood tests to assess kidney status and should not take this medication if kidney function falls below a certain level. Rare skin conditions such as acute pancreatitis or bullous pemphigoid may occur; patients experiencing persistent abdominal pain or unusual skin symptoms should consult a doctor immediately. This medication may lower vitamin B12 levels; long-term users should be tested for vitamin B12 deficiency and supplemented as needed. Alcohol consumption may increase the risk of lactic acidosis; it is advisable to avoid alcohol while taking this medication. If contrast agents are required for radiological examinations, the medication should be discontinued for a certain period before and after the tests, and kidney function should be assessed. Elderly patients or those with impaired kidney function should have their dosage adjusted and monitor kidney function regularly. Pregnant women or those planning to become pregnant should preferably avoid using this medication; insulin therapy is recommended if blood glucose control is necessary. The safety and efficacy of this medication have not been established in children and adolescents, so use in this population is not recommended. There is insufficient data on the effects of this medication on driving or operating machinery, thus caution is warranted during such activities. In cases of overdose, gastrointestinal disturbances or lactic acidosis may occur; if any adverse symptoms arise, prompt medical attention is required. Store this medication out of the reach of children, away from moisture, and in its original container.

Side effects

  • Lactic acidosis
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
Show 133 more
  • abdominal pain
  • formation of oral ulcers
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blistering pemphigoid
  • severe and disabling arthralgia
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • nasopharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • decreased and deficient vitamin B12
  • increased triglycerides in the blood
  • increased urine albumin/creatinine ratio
  • positive urine leukocytes
  • decreased hemoglobin
  • increased potassium in the blood
  • increased creatinine in the blood
  • increased creatine phosphokinase
  • increased ALT
  • increased AST
  • itching
  • insomnia
  • depression
  • anxiety
  • hypotension
  • flushing
  • hearing loss
  • dizziness
  • erectile dysfunction
  • thyroid enlargement
  • kidney transplant failure
  • anemia
  • cerebral infarction
  • speech disorders
  • Alzheimer’s dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscal injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • cholelithiasis
  • dizziness
  • fever
  • chest discomfort
  • weakness
  • pain
  • osteoarthritis
  • limb pain
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • male pattern hair loss
  • hyperhidrosis
  • hair loss
  • dermatitis
  • insomnia
  • depression
  • hypertension
  • confusion
  • nocturia
  • dermatitis
  • hyperglycemia
  • decreased appetite
  • insufficient control of diabetes
  • malnutrition
  • hyponatremia
  • dehydration
  • headache
  • paresthesia
  • postherpetic neuralgia
  • hemiparesis
  • syncope
  • drowsiness
  • nosebleed
  • oropharyngeal pain
  • speech disorders
  • nasal hemorrhage
  • vocal cord polyp
  • benign prostatic hyperplasia
  • vitreous hemorrhage
  • stomatitis
  • mediastinitis
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • increased creatinine in the blood
  • facial edema
  • fever
  • chest pain
  • ligament sprain
  • upper limb fracture
  • contusion
  • bone contusion
  • concussion
  • bone fracture
  • laceration

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. Additionally, it is safest to store it at room temperature between 1 to 30 degrees Celsius, avoiding extremely hot or cold environments.

Appearance and packaging

Appearance

Orange, double convex oval film-coated tablets

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.